148 related articles for article (PubMed ID: 1371564)
1. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
Seidman AD; Scher HI; Petrylak D; Dershaw DD; Curley T
J Urol; 1992 Mar; 147(3 Pt 2):931-4. PubMed ID: 1371564
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer].
Awakura Y; Yamamoto M; Fukuzawa S; Itoh N; Nonomura M; Fukuyama T
Hinyokika Kiyo; 2000 Jul; 46(7):449-52. PubMed ID: 10965448
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.
Hudes GR; Greenberg R; Krigel RL; Fox S; Scher R; Litwin S; Watts P; Speicher L; Tew K; Comis R
J Clin Oncol; 1992 Nov; 10(11):1754-61. PubMed ID: 1383436
[TBL] [Abstract][Full Text] [Related]
4. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
Hudes G; Einhorn L; Ross E; Balsham A; Loehrer P; Ramsey H; Sprandio J; Entmacher M; Dugan W; Ansari R; Monaco F; Hanna M; Roth B
J Clin Oncol; 1999 Oct; 17(10):3160-6. PubMed ID: 10506613
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
6. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
Miller JI; Ahmann FR; Drach GW; Emerson SS; Bottaccini MR
J Urol; 1992 Mar; 147(3 Pt 2):956-61. PubMed ID: 1371568
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer.
Attivissimo LA; Fetten JV; Kreis W
Am J Clin Oncol; 1996 Dec; 19(6):581-3. PubMed ID: 8931676
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
Smith MR; Kaufman D; Oh W; Guerin K; Seiden M; Makatsoris T; Manola J; Kantoff PW
Cancer; 2000 Oct; 89(8):1824-8. PubMed ID: 11042579
[TBL] [Abstract][Full Text] [Related]
9. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer.
Albrecht W; Van Poppel H; Horenblas S; Mickisch G; Horwich A; Serretta V; Casetta G; Maréchal JM; Jones WG; Kalman S; Sylvester R
Br J Cancer; 2004 Jan; 90(1):100-5. PubMed ID: 14710214
[TBL] [Abstract][Full Text] [Related]
11. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone.
Akerley W; Butera J; Wehbe T; Noto R; Stein B; Safran H; Cummings F; Sambandam S; Maynard J; Di Rienzo G; Leone L
Cancer; 2002 Mar; 94(6):1654-60. PubMed ID: 11920525
[TBL] [Abstract][Full Text] [Related]
12. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
[TBL] [Abstract][Full Text] [Related]
13. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
Khil MS; Kim JH; Bricker LJ; Cerny JC
Cancer J Sci Am; 1997; 3(5):289-96. PubMed ID: 9327153
[TBL] [Abstract][Full Text] [Related]
14. Megestrol acetate in relapsed carcinoma of prostate.
Daniel F; MacLeod PM; Tyrrell CJ
Br J Urol; 1990 Mar; 65(3):275-7. PubMed ID: 2186841
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
Zelefsky MJ; Kelly WK; Scher HI; Lee H; Smart T; Metz E; Schwartz L; Fuks Z; Leibel SA
J Clin Oncol; 2000 May; 18(9):1936-41. PubMed ID: 10784635
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer.
Arai Y; Yoshiki T; Yoshida O
J Urol; 1990 Dec; 144(6):1415-9. PubMed ID: 1700155
[TBL] [Abstract][Full Text] [Related]
17. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay.
Tarle M; Radoś N
Prostate; 1991; 19(1):23-33. PubMed ID: 1715080
[TBL] [Abstract][Full Text] [Related]
18. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
[TBL] [Abstract][Full Text] [Related]
20. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
